On May 4, Nathaniel Hogrebe, PhD; Matthew Ishahak, PhD; and Jeffrey Millman, PhD had their review titled “Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes,” published in Cell Stem Cell.
In diabetes treatment, there is great potential for islet-like endocrine clusters from human pluripotent stem cells (hPSCs) to provide a limitless source of insulin-producing islets. For this cell therapy to become prevalent, the manufacturing of highly functional and well-characterized islets from hPSCs at scale is essential.
In the review, the authors provide analysis of recent advances and characterizations of highly functional SC-islets. Including an in-depth discussion on how successful SC-islet replacement strategies can ensure graft viability and post-transplantation safety by preventing significant cell loss and avoiding long-term immune rejection.
Nathaniel J. Hogrebe, Matthew Ishahak, Jeffrey R. Millman. Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes. Cell Stem Cell. Volume 30, Issue 5. 2023. Pages 530-548. ISSN 1934-5909. https://doi.org/10.1016/j.stem.2023.04.002.